BR112020015688A8 - Formulações tópicas que compreendem tofacitinibe - Google Patents

Formulações tópicas que compreendem tofacitinibe

Info

Publication number
BR112020015688A8
BR112020015688A8 BR112020015688A BR112020015688A BR112020015688A8 BR 112020015688 A8 BR112020015688 A8 BR 112020015688A8 BR 112020015688 A BR112020015688 A BR 112020015688A BR 112020015688 A BR112020015688 A BR 112020015688A BR 112020015688 A8 BR112020015688 A8 BR 112020015688A8
Authority
BR
Brazil
Prior art keywords
topical formulations
formulations including
tofacitinib
including tofacitinib
topical formulation
Prior art date
Application number
BR112020015688A
Other languages
English (en)
Other versions
BR112020015688A2 (pt
Inventor
Chen Chih-Ming
Liaw Ling-Ying
Liu Fan-Lun
Liao Shih-Fen
Chen Chou-Hsiung
Kao Yu-Han
chen Yu-yin
Lu Guang-Wei
Original Assignee
Twi Pharmaceuticals Inc
Twi Biotechnology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Twi Pharmaceuticals Inc, Twi Biotechnology Inc filed Critical Twi Pharmaceuticals Inc
Publication of BR112020015688A2 publication Critical patent/BR112020015688A2/pt
Publication of BR112020015688A8 publication Critical patent/BR112020015688A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Trata-se de uma formulação tópica que compreende (a) uma quantidade terapeuticamente eficaz de tofacitinibe; (b) pelo menos um solvente; e (c) opcionalmente, é fornecido um ou mais outros excipientes farmaceuticamente aceitáveis. Também é fornecido um método para o tratamento e/ou prevenção de doenças autoimunes em um sujeito que administra a dita formulação tópica.
BR112020015688A 2018-01-31 2019-01-22 Formulações tópicas que compreendem tofacitinibe BR112020015688A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624567P 2018-01-31 2018-01-31
US62/624,567 2018-01-31
PCT/US2019/014524 WO2019152232A1 (en) 2018-01-31 2019-01-22 Topical formulations comprising tofacitinib

Publications (2)

Publication Number Publication Date
BR112020015688A2 BR112020015688A2 (pt) 2020-12-08
BR112020015688A8 true BR112020015688A8 (pt) 2022-07-05

Family

ID=67393025

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020015688A BR112020015688A8 (pt) 2018-01-31 2019-01-22 Formulações tópicas que compreendem tofacitinibe

Country Status (11)

Country Link
US (1) US10960006B2 (pt)
EP (1) EP3746086A4 (pt)
JP (1) JP7324210B2 (pt)
KR (1) KR20200128657A (pt)
CN (1) CN111670036A (pt)
AU (1) AU2019213835A1 (pt)
BR (1) BR112020015688A8 (pt)
CA (1) CA3089108A1 (pt)
SG (1) SG11202006782YA (pt)
TW (1) TW201940174A (pt)
WO (1) WO2019152232A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210212931A1 (en) * 2018-01-31 2021-07-15 Twi Pharmaceuticals, Inc. Topical formulations comprising tofacitinib
WO2019236596A1 (en) * 2018-06-04 2019-12-12 Chemistryrx. Topical compositions for stimulating hair growth
US20190381046A1 (en) * 2018-06-14 2019-12-19 Andrew HANNA Tofacitinib and baclofen compositions and applications
US20200009077A1 (en) * 2018-07-03 2020-01-09 TRUETIVA, Inc. Compositions for treating dermatological diseases
CA3157594A1 (en) * 2019-11-08 2021-05-14 Nitin JOSHI Topical delivery of tofacitinib using ionic liquid
US11766438B2 (en) * 2020-04-24 2023-09-26 Slayback Pharma Llc Pharmaceutical compositions of tofacitinib for oral administration
CN113712919A (zh) * 2020-05-25 2021-11-30 南京帝昌医药科技有限公司 治疗秃发脱发的枸橼酸托法替布喷雾剂的制备
WO2022022434A1 (zh) * 2020-07-27 2022-02-03 杭州和正医药有限公司 含托法替尼药学上可接受的盐的药物组合物、制剂及应用
CN111728953B (zh) * 2020-07-29 2023-08-08 中国科学院上海药物研究所 一种托法替布或其盐的缓释制剂及其制备方法
CN112402615A (zh) * 2020-11-11 2021-02-26 长沙晶易医药科技有限公司 一种用于治疗斑秃的复方外用制剂及其制备方法
US20220233544A1 (en) * 2021-01-28 2022-07-28 Chemistryrx Treatments for skin conditions
CN113730335B (zh) * 2021-09-18 2023-07-28 中国药科大学 一种托法替布外用药物组合物及其应用
WO2023143345A1 (zh) * 2022-01-25 2023-08-03 杭州和正医药有限公司 一种含托法替尼的局部用药的药物组合物、制剂及应用
CN116942602B (zh) * 2023-09-20 2023-12-22 北京普祺医药科技股份有限公司 一种枸橼酸托法替布药物组合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301023B2 (en) * 2001-05-31 2007-11-27 Pfizer Inc. Chiral salt resolution
US7776877B2 (en) * 2007-06-22 2010-08-17 Chemocentryx, Inc. N-(2-(hetaryl)aryl) arylsulfonamides and N-(2-(hetaryl) hetaryl arylsulfonamides
KR20120115413A (ko) 2007-07-11 2012-10-17 화이자 인코포레이티드 안구 건조증 치료용 약학 조성물 및 방법
US9198911B2 (en) * 2010-11-02 2015-12-01 The Trustees Of Columbia University In The City Of New York Methods for treating hair loss disorders
WO2012099968A1 (en) * 2011-01-19 2012-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating skin cancer associated diseases
EP2691395B1 (en) 2011-03-28 2017-08-30 ratiopharm GmbH Processes for preparing tofacitinib salts
WO2012137111A1 (en) * 2011-04-08 2012-10-11 Pfizer Inc. Crystalline and non- crystalline forms of tofacitinib, and a pharmaceutical composition comprising tofacitinib and a penetration enhancer
WO2014013014A1 (en) * 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
JP6473134B2 (ja) * 2013-03-15 2019-02-20 メディシス ファーマシューティカル コーポレイション フルニソリドの局所用組成物および治療方法
EP3013336A1 (en) * 2013-06-24 2016-05-04 Tigercat Pharma Inc. Use of nk-1 receptor antagonist serlopitant in pruritus
MY185593A (en) * 2013-09-18 2021-05-24 Bcn Peptides Sa Cortistatin analogues for the treatment of inflammatory and/or immune diseases
EP3054959B1 (en) * 2013-10-08 2020-01-08 Promedior Inc. Methods for treating fibrotic cancers
SG11201607881SA (en) * 2014-03-31 2016-10-28 Kirin Amgen Inc Methods of treating nail and scalp psoriasis
WO2016025686A1 (en) * 2014-08-15 2016-02-18 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
KR20180002838A (ko) * 2015-05-07 2018-01-08 더 트러스티스 오브 콜롬비아 유니버시티 인 더 시티 오브 뉴욕 모발 생장을 촉진하기 위한 방법 및 조성물
WO2017119928A1 (en) * 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations

Also Published As

Publication number Publication date
US10960006B2 (en) 2021-03-30
TW201940174A (zh) 2019-10-16
KR20200128657A (ko) 2020-11-16
US20190231782A1 (en) 2019-08-01
BR112020015688A2 (pt) 2020-12-08
CN111670036A (zh) 2020-09-15
SG11202006782YA (en) 2020-08-28
CA3089108A1 (en) 2019-08-08
JP2021512096A (ja) 2021-05-13
EP3746086A4 (en) 2021-10-20
EP3746086A1 (en) 2020-12-09
AU2019213835A1 (en) 2020-08-06
WO2019152232A1 (en) 2019-08-08
JP7324210B2 (ja) 2023-08-09

Similar Documents

Publication Publication Date Title
BR112020015688A8 (pt) Formulações tópicas que compreendem tofacitinibe
CL2017002939A1 (es) Composiciones farmacéuticas tópicas
CO2021000174A2 (es) Composiciones tópicas para el alivio del dolor
AR107871A1 (es) Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos
CR20170563A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
EA201070940A1 (ru) Жидкая лекарственная форма фсг
NZ749192A (en) Ar+ breast cancer treatment methods
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
BR112018007947A2 (pt) uso de antagonistas de receptor ep4 para o tratamento de câncer de fígado associado a nash
AR085662A1 (es) Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112017016087A2 (pt) formulações para coxim articular adiposo e métodos de uso das mesmas
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
BR112016000335A8 (pt) método de tratamento da rosácea papulopustular, de tratamento de lesões inflamatórias da rosácea papulopustular e uso de uma composição farmacêutica
CY1125075T1 (el) Εκχυλισμα salvia haenkei σαν δραστικος παραγοντας στις διαδικασιες επανεπιθηλιωσης και επουλωσης ιστων
CL2019002172A1 (es) Agente terapéutico para enfermedades del hígado.
EA202190308A1 (ru) Применение пролекарств рилузола для лечения болезни альцгеймера
MX2020000164A (es) Formulaciones de isotretinoína para la mucosa oral y métodos para usar las mismas.
CO2020001887A2 (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático
BR112015012497A2 (pt) combinações farmacêuticas
CO2020001881A2 (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco trometamina y clorhidrato de tramadol
BR112018073396A2 (pt) combinação de antagonistas, uso de uma combinação, método para o tratamento de desordens cognitivas, composto, método para o tratamento de doença de alzheimer e composição farmacêutica
CO2022004947A2 (es) Regímenes de dosificación para el tratamiento de pacientes con carcinoma de células escamosas avanzado localmente
BR112023007912A2 (pt) Formas cristalinas de um composto inibidor de kras g12c
BR112021026561A2 (pt) Uso de uma composição farmacêutica na fabricação de um medicamento para a prevenção ou tratamento de doença hepática

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: TWI BIOTECHNOLOGY, INC. (TW)